Posts

Posted on

Mammoth Energy Releases Additional Information Regarding Work Performed in Puerto Rico

OKLAHOMA CITY, June 08, 2021 (GLOBE NEWSWIRE) — Mammoth Energy Services, Inc. (“Mammoth” or the “Company”) (NASDAQ:TUSK) today announced that it has posted to its website additional information addressing two documents recently released by the Federal Emergency Management Agency (“FEMA”) that relate to hurricane repair work performed by Cobra Acquisitions LLC (“Cobra”) in Puerto Rico.

FEMA released a Determination Memorandum dated May 26, 2021, related to the first of two contracts Cobra successfully performed for the Puerto Rico Electric Power Authority (“PREPA”). Cobra and PREPA executed the Emergency Master Service Agreement for PREPA’s Electrical Grid Repairs – Hurricane Maria on October 19, 2017 (the “Contract”). PREPA has 60 days from the receipt of FEMA’s Determination Memorandum to file an appeal.

In addition to the Determination Memorandum, the Company also recently obtained a draft Cost Analysis prepared by FEMA in response to the recommendation of the Department of Homeland Security’s Office of Inspector General (“OIG”) made in an OIG report dated July 3, 2019 (OIG-19-052). The OIG recommended that FEMA conduct a comprehensive analysis of Cobra’s Contract costs and disallow reimbursement to PREPA of any Cobra Contract costs that are not reasonable. In order to address the OIG recommendation, FEMA and the United States Army Corps of Engineers (“USACE”) analyzed the reasonableness of the actual Cobra costs for which PREPA is seeking reimbursement from FEMA.

Arty Straehla, chief executive officer of Mammoth commented, “Today, we release a fifth confirmation that the work performed by our subsidiary Cobra in Puerto Rico was both within the scope of the PREPA contract and was at a lower overall cost than other contractors on the island. This information, which is contained in reports produced by both FEMA and USACE, adds to previous confirmations, including (i) the FEMA Determination Memorandum dated December 23, 2017, (ii) the FEMA memorandum dated April 22, 2019, (iii) Emergency Contract – Cost Validation Report prepared by the Homeland Security Operational and Analysis Center dated March 28, 2019 (the ‘Rand Report’) and (iv) Freedom of Information Act data, all of which can be found on our website www.mammothenergy.com. The documentation continues to show that our team performed a difficult job in a difficult environment to save lives and aid the people of Puerto Rico in their time of need. In addition to this recently obtained information, we have also recently become aware in court filings made by PREPA that FEMA has obligated approximately $250 million for costs incurred under the second contract.”

FEMA Cost Analysis

The scope of FEMA’s Cost Analysis included the following:

  1. Evaluate Cobra’s overall level of effort and work productivity based on the statement of work (“SOW”) developed by FEMA;
  2. Compare Cobra’s actual costs to those of other electrical contractors that performed similar work when the data existed. FEMA reviewed Cobra’s cost of work performed per transmission line (“TL”) and distribution line (“DL”), Cobra’s overall actual average daily rate, and the daily per diem to cover lodging and living expenses; and
  3. Reviewed USACE’s report and consider its recommendations prior to making a conclusion on cost reasonableness.

After completing its Cost Analysis, FEMA came to the conclusions below in the draft report. A full copy of the draft findings can be found on the Mammoth website: https://ir.mammothenergy.com/events-presentations.

  • Page 13 – Cobra’s overall average rate is lower than all other contractors reviewed.
  • Page 14 – Given the condition and circumstances on the island, the evaluation of all data available to assess the level of effort for the work performed, and the comparison to other contract costs, FEMA found that Cobra’s costs per tower for both transmission and distribution lines for the work captured on this project appear reasonable.
  • Page 15 – (USACE Analysis) Cobra’s duration of work for electrical work appears to be reasonable.
  • Page 19 – Cobra’s overall average rate is lower than all other contractors reviewed. If the average 9% tax markup is added, the rates fall in line with the MOUs and are still lower than Whitefish rates.
  • Page 20 – Based on the results of the FEMA and USACE analyses, FEMA has no reason to believe that the cost of the work performed by Cobra is not reasonable.

FEMA’s Determination Memorandum and Cost Analysis raised two contract compliance issues. Below we summarize the Contract compliance issues identified by FEMA, along with a brief summary of Cobra’s response. A full copy of the documentation can be found on the Mammoth website: https://ir.mammothenergy.com/events-presentations.

   
Contract Compliance Issue Cobra Response
   
Excess Man Count- FEMA identified 43 days when Cobra exceeded the highest allowable staffing level agreed to in Exhibit 1-B Contractors’ Rate Schedule of 882 personnel without the written consent of PREPA. FEMA identified $24,439,810.49 related to this issue. At the request of Puerto Rico and the full knowledge and consent of PREPA and FEMA, Cobra agreed to bring on a subcontractor that had previously worked for USACE and already had both personnel and equipment in Puerto Rico. The addition of these personnel was in full compliance with the Contract.   
Mobilization Expenses- FEMA identified that Cobra began billing for the daily minimum amount due of $1,563,000, based on 250 linemen, starting on October 25, 2017; however, Cobra did not reach the required minimum number of linemen on the island until November 12, 2017. As a result, FEMA determined that $21,451,272.51 was ineligible. Further, FEMA determined that $133,800 in lodging rentals were ineligible.

FEMA cited Section 4.3 of the Contract that “payment will be made for actual days worked”.

 The Contract provided that Cobra would be paid a daily minimum amount of $1,563,000. Cobra began billing the daily minimum on October 25, 2017, after Cobra supplied PREPA with a roster of 250 linemen that it was mobilizing to the island.

Cobra incurred $133,800 in lodging for the Management Team for Operations and Safety personnel included in Exhibit B of the Contract. These personnel were housed in San Juan to be closer to PREPA’s offices and allow the Management Team to be more accessible to PREPA for regular meetings. The charges were invoiced to PREPA at cost. These costs were necessary to Cobra’s performance and are reimbursable under the Contract.

FEMA’s citation of Section 4.3 in regards to mobilization expenses is a mischaracterization of the contractual terms. Section 4.3 relates to the termination of work, not the mobilization of lineman.

About Mammoth
Energy Services, Inc.

Mammoth is an integrated, growth-oriented energy service company serving companies engaged in the construction and repair of the electric grid for private utilities, public investor-owned utilities and co-operative utilities through its energy infrastructure services and the exploration and development of North American onshore unconventional oil and natural gas reserves. Mammoth’s suite of services and products include: infrastructure services, well completion services, natural sand and proppant services, drilling services and other energy services.

Investor Contact:

Mark Layton, Chief Financial Officer
[email protected]
(405) 608-6007

Media Contact:

Peter Mirijanian
[email protected]
(202) 464-8803



Posted on

Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software

PR Newswire

LAVAL, QB and ST. PAUL, Minn., June 8, 2021 /PRNewswire/ — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today announced that its affiliate has entered into an agreement with Lochan LLC (“Lochan”) to develop the next-generation of Bausch + Lomb’s eyeTELLIGENCE™ clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed to allow surgeons to seamlessly integrate all aspects of the cataract, retinal and refractive surgery processes to maximize their overall practice efficiency. The companies expect to launch the initial phase of this next-generation software in 2022.

“Similar to what is being seen across the entire health care spectrum, ophthalmologists are under tremendous pressure to find ways to increase their efficiency and optimize workflow while continuing to deliver the highest level of patient care. The need for solutions that help them pursue this goal is massive,” said Joseph Gordon, U.S. president, Bausch + Lomb. “In 2018, we started our journey to deliver on this need when we became the first company to connect the operating room to the cloud using our eyeTELLIGENCE technology. The agreement with Lochan propels us into the next phase of this journey to further enhance surgeon’s ability to improve practice efficiency.”

Ophthalmic surgical procedures require a sophisticated, multi-step process that involves patient diagnostics, clinical treatment planning, surgery planning, post-op analysis and more. Today, the transitions between each step require the manual transfer of data, which can be time consuming and lead to unintended human error. The next-generation eyeTELLIGENCE™ software platform is being designed to create opportunities to streamline this complex process, resulting in a more seamless connection from pre surgery assessment to treatment planning and execution to post surgery evaluation.

“As a practicing surgeon, I have experienced first-hand the disconnect that exists between the different phases of the surgical planning process and the lack of interconnectivity between technologies that we use,” said Mark Lobanoff, M.D., director of refractive surgery, North Suburban Eye Specialists, Minneapolis, MN, and founder, Lochan LLC. “Just as Bausch + Lomb introduced eyeTELLIGENCE™ to help address these challenges, I founded Lochan because I understood the benefits that digital integration could bring. That’s why I believe that together, we will be able to bring the capabilities of eyeTELLIGENCE™ to the next level — helping surgeons use data to make more informed and faster procedural and treatment decisions.”

About eyeTELLIGENCE™ Platform
In 2018, Bausch + Lomb launched the eyeTELLIGENCE™ cloud-based digital platform as a way to help surgeons work smarter and find new ways to use data to maximize their overall practice efficiency. Today, eyeTELLIGENCE™, which is exclusively available on the Stellaris Elite™ vision enhancement system, is used by surgeons across the United States.

About Lochan
Lochan is a software development company focused on using advanced analytics and artificial intelligence to bring novel solutions to complex ophthalmic calculations. Lochan specializes in bringing sui generis approaches to create cloud-based software platforms that are both unique and paradigm shifting. Our goal is to give each surgeon the most accurate and powerful software tools in the world while simultaneously making them simple to use and effortlessly efficient. Visit https://lochan.mn/ for more information.

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.com.  

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

®/TM
 are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names and/or logos are trademarks of the respective owners.

© 2021 Bausch & Lomb Incorporated or its affiliates.


ETG.0015.USA.21


Lochan Media Contact:


Bausch Health Investor Contact:

Mark Lobanoff

Arthur Shannon


[email protected]  


[email protected]

(763) 772-7173

(514) 865-3855

(877) 281-6642 (toll free)


Bausch Health Media Contact:

Lainie Keller


[email protected]

(908) 927-1198

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch–lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software-301307293.html

SOURCE Bausch Health Companies Inc.

Posted on

Philip Morris International Inc. (PMI) Presents at the 2021 Deutsche Bank Global Consumer Conference; Reaffirms 2021 Full-Year Adjusted Diluted EPS Outlook

Philip Morris International Inc. (PMI) Presents at the 2021 Deutsche Bank Global Consumer Conference; Reaffirms 2021 Full-Year Adjusted Diluted EPS Outlook

NEW YORK–(BUSINESS WIRE)–
Regulatory News:

Philip Morris International Inc.’s (NYSE:PM) Chief Financial Officer, Emmanuel Babeau, will address investors today at the Deutsche Bank Global Consumer Conference.

The presentation and Q&A session will be conducted in a virtual format, beginning at approximately 8:00 a.m. Eastern Time. A live audio call for the entire PMI session will be held in a listen-only mode. Investors and other parties may register for the call at www.pmi.com/2021deutschebank, in order to receive dial-in instructions and numbers. Presentation slides will be available on the same site.

An archived copy of the call will be available at www.pmi.com/2021deutschebank until 5:00 p.m. Eastern Time on Wednesday, July 7, 2021. The archived call can also be accessed on iOS or Android devices by downloading PMI’s free Investor Relations Mobile Application at www.pmi.com/irapp.

2021 Full-Year Adjusted Diluted EPS Forecast

 

 

Full-Year

 

 

2021

Forecast

 

2020

 

Organic

Growth

 

 

 

 

 

 

 

 

 

 

 

Adjusted Diluted EPS1

  

$5.95

–

$6.05

 

$5.17

 

 

 

 

Currency

 

(0.20)

 

 

 

 

 

 

Adjusted Diluted EPS, excluding currency

  

$5.75

–

$5.85

 

$5.17

 

11%

–

13%

1.

 

2021 Forecast excludes asset impairment and exit costs of $(0.02). 2020 excludes asset impairment and exit costs of $(0.08), fair value adjustment for equity security investments of $(0.04), tax items of $0.06 and a Brazil indirect tax credit of $0.05.

PMI reaffirms its full-year adjusted diluted EPS forecast, provided on April 20, 2021, to be in a range of $5.95 to $6.05, at the then prevailing exchange rates. On an organic basis, this forecast represents a projected increase of around 11% to 13% versus adjusted diluted EPS of $5.17 in 2020, as outlined in the table above.

2021 Second-Quarter Adjusted Diluted EPS Assumption

PMI continues to expect second-quarter adjusted diluted EPS in a range of $1.50 to $1.55, as communicated on April 20, 2021, including a favorable currency impact, at the then prevailing exchange rates, of around $0.04 per share, notably reflecting:

  • Strong sequential and year-over-year PMI heated tobacco unit shipment and in-market sales volume growth, driven by EU, Japan, Russia;
  • Heated tobacco unit shipment volume of around 24 billion units;
  • Strong organic net revenue growth, partly driven by a favorable comparison versus the second quarter of 2020;
  • Continued improvement in adjusted operating income margin on an organic basis; and
  • A partial reversal of the approximately $0.08 per share benefit recorded in the first quarter related to the timing of specific factors, notably associated with shipments in certain markets and the phasing of commercial investments.

PMI is scheduled to report its second-quarter 2021 earnings results on Tuesday, July 20, 2021.

2021 Full-Year Forecast Assumptions

This forecast assumes:

  • A gradual improvement in the general operating environment, with potential volatility around the duration and effects of pandemic-related mobility restrictions across PMI’s key markets;
  • Lack of near-term recovery in PMI’s duty-free business given the uncertain outlook for global travel, with current dynamics persisting through year end;
  • A limited impact from the current global shortage of semiconductors on the supply of our electronic devices to consumers;
  • An estimated total international industry volume progression, excluding China and the U.S., of approximately -3% to flat;
  • A total cigarette and heated tobacco unit shipment volume progression for PMI of approximately -2% to +1%;
  • Heated tobacco unit shipment volume of 95 to 100 billion units;
  • Net revenue growth of approximately 5% to 7% on an organic basis;
  • An increase in adjusted operating income margin of around 200 basis points on an organic basis;
  • Operating cash flow of around $11 billion at prevailing exchange rates and subject to year-end working capital requirements;
  • Capital expenditures of approximately $0.8 billion;
  • An effective tax rate, excluding discrete tax events, of around 22%;
  • No share repurchases;
  • A second half of 2021 reflecting:

    • The assumption that many of PMI’s key markets will have largely emerged from pandemic-related restrictions;
    • Continued robust organic net revenue growth;
    • Incremental commercial investments, compared to the first half of 2021, of approximately $300 to $400 million; and
    • Lower organic adjusted operating income margin expansion compared to the first half of 2021.

The foregoing is underpinned by the assumption that, even in the event of prolonged pandemic-related restrictions, there will not be a return to the depressed consumption levels of the second quarter of 2020. This assumption is consistent with the less severe impact on consumption levels observed in the second half of 2020 as COVID-19 spread in a number of markets.

This forecast excludes the impact of any future acquisitions, unanticipated or unquantifiable asset impairment and exit cost charges, future changes in currency exchange rates, further developments pertaining to the judgment in the two Québec Class Action lawsuits and the Companies’ Creditors Arrangement Act (CCAA) protection granted to PMI’s Canadian subsidiary, Rothmans, Benson & Hedges, Inc. (RBH), any unusual events, any intensification of the global shortage of semiconductors and the related impact on the supply of our electronic devices, and any COVID-19-related developments different from the assumptions set forth in the company’s forecast.

Factors described in the Forward-Looking and Cautionary Statements section of this release represent continuing risks to these projections.

Saudi Arabia Customs Assessments

On June 1, 2021, the Customs Appeal Committee in Riyadh notified our distributors in Saudi Arabia of its decisions to largely reject the distributors’ challenges of the Saudi Arabia Customs General Authority assessments requiring them to pay additional customs duties described in our Form 10-Q that was filed with the U.S. Securities and Exchange Commission for the quarter ended March 31, 2021. The assessments relate to fees paid by the distributors under their agreements with our subsidiary for exclusive rights to distribute our products in Saudi Arabia during the period of 2014 through 2018.

PMI is evaluating the impact of the decisions and the related amount that it will accrue. PMI currently estimates an adverse impact on its 2021 full-year reported diluted EPS of up to $0.18 per share. The accrued amount will be excluded from PMI’s 2021 full-year adjusted financial results.

Forward-Looking and Cautionary Statements

This press release contains projections of future results and other forward-looking statements. Achievement of future results is subject to risks, uncertainties and inaccurate assumptions. In the event that risks or uncertainties materialize, or underlying assumptions prove inaccurate, actual results could vary materially from those contained in such forward-looking statements. Pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, PMI is identifying important factors that, individually or in the aggregate, could cause actual results and outcomes to differ materially from those contained in any forward-looking statements made by PMI.

PMI’s business risks include: excise tax increases and discriminatory tax structures; increasing marketing and regulatory restrictions that could reduce our competitiveness, eliminate our ability to communicate with adult consumers, or ban certain of our products; health concerns relating to the use of tobacco and other nicotine-containing products and exposure to environmental tobacco smoke; litigation related to tobacco use and intellectual property; intense competition; the effects of global and individual country economic, regulatory and political developments, natural disasters and conflicts; changes in adult smoker behavior; lost revenues as a result of counterfeiting, contraband and cross-border purchases; governmental investigations; unfavorable currency exchange rates and currency devaluations, and limitations on the ability to repatriate funds; adverse changes in applicable corporate tax laws; adverse changes in the cost, availability, and quality of tobacco and other agricultural products and raw materials, as well as components and materials for our electronic devices; and the integrity of our information systems and effectiveness of our data privacy policies. PMI’s future profitability may also be adversely affected if we are unsuccessful in our attempts to produce and commercialize reduced-risk products (“RRPs”) or if regulation or taxation do not differentiate between such products and cigarettes; if we are unable to successfully introduce new products, promote brand equity, enter new markets or improve our margins through increased prices and productivity gains; if we are unable to expand our brand portfolio internally or through acquisitions and the development of strategic business relationships; or if we are unable to attract and retain the best global talent. Future results are also subject to the lower predictability of our reduced-risk product category’s performance.

The COVID-19 pandemic has created significant societal and economic disruption, and resulted in closures of stores, factories and offices, and restrictions on manufacturing, distribution and travel, all of which will adversely impact our business, results of operations, cash flows and financial position during the continuation of the pandemic. Our business continuity plans and other safeguards may not be effective to mitigate the impact of the pandemic. Currently, significant risks include our diminished ability to convert adult smokers to our RRPs, significant volume declines in our duty-free business and certain other key markets, disruptions or delays in our manufacturing and supply chain, increased currency volatility, and delays in certain cost saving, transformation and restructuring initiatives. Our business could also be adversely impacted if key personnel or a significant number of employees or business partners become unavailable due to the COVID-19 outbreak. The significant adverse impact of COVID-19 on the economic or political conditions in markets in which we operate could result in changes to the preferences of our adult consumers and lower demand for our products, particularly for our mid-price or premium-price brands. Continuation of the pandemic could disrupt our access to the credit markets or increase our borrowing costs. Governments may temporarily be unable to focus on the development of science-based regulatory frameworks for the development and commercialization of RRPs or on the enforcement or implementation of regulations that are significant to our business. In addition, messaging about the potential negative impacts of the use of our products on COVID-19 risks may lead to increasingly restrictive regulatory measures on the sale and use of our products, negatively impact demand for our products, the willingness of adult consumers to switch to our RRPs and our efforts to advocate for the development of science-based regulatory frameworks for the development and commercialization of RRPs.

The impact of these risks also depends on factors beyond our knowledge or control, including the duration and severity of the pandemic, its recurrence in our key markets, actions taken to contain its spread and to mitigate its public health effects, and the ultimate economic consequences thereof.

PMI is further subject to other risks detailed from time to time in our publicly filed documents, including the Form 10-Q for the quarter ended March 31, 2021. PMI cautions that the foregoing list of important factors is not a complete discussion of all potential risks and uncertainties. PMI does not undertake to update any forward-looking statement that we may make from time to time, except in the normal course of its public disclosure obligations.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, its shareholders and its other stakeholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products, associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. In addition, PMI ships versions of its IQOS Platform 1 device and consumables to Altria Group, Inc. for sale under license in the U.S., where these products have received marketing authorizations from the U.S. Food and Drug Administration (FDA) under the premarket tobacco product application (PMTA) pathway; the FDA has also authorized the marketing of a version of IQOS and its consumables as a Modified Risk Tobacco Product (MRTP), finding that an exposure modification order for these products is appropriate to promote the public health. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free product portfolio includes heat-not-burn and nicotine-containing vapor products. As of March 31, 2021, PMI’s smoke-free products are available for sale in 66 markets in key cities or nationwide, and PMI estimates that approximately 14.0 million adults around the world have already switched to IQOS and stopped smoking. For more information, please visit www.pmi.com and www.pmiscience.com.

Investor Relations:

New York: +1 (917) 663 2233

Lausanne: +41 (0)58 242 4666

[email protected]

Media:

Lausanne: +41 (0)58 242 4500

[email protected]

KEYWORDS: United States North America Canada New York

INDUSTRY KEYWORDS: Tobacco Retail

MEDIA:

Logo
Logo
Posted on

CDC Renews Partnership with Palantir for Disease Monitoring and Outbreak Response

CDC Renews Partnership with Palantir for Disease Monitoring and Outbreak Response

DENVER–(BUSINESS WIRE)–
Palantir Technologies Inc. (NYSE:PLTR) announced today it was awarded a $7.4 million one-year contract renewal with the U.S. Centers for Disease Control and Prevention (CDC) to continue to provide an outbreak response and disease surveillance solution for the Data Collation and Integration for Public Health Event Response (DCIPHER) Program.

This award deepens Palantir’s more than decade-long partnership with the CDC on disease surveillance efforts and is distinct from Palantir’s COVID-19 response work with U.S. federal health agencies. Palantir’s partnership with the CDC dates back to 2010 when it was initially brought in to help the agency better manage foodborne outbreaks.

DCIPHER is designed to assist public health experts in routine disease surveillance and outbreak management for real-time events. The core platform, based on Palantir Foundry, facilitates the collection and integration of various sources of epidemiological, surveillance, and laboratory data and provides tools for multiple organizations, including CDC’s jurisdictional partners, to investigate and take action.

Examples of programs currently using DCIPHER include the System for Enteric Disease Response, Investigation, and Coordination (SEDRIC) and the National Wastewater Surveillance System (NWSS) within the CDC’s Division of Foodborne, Waterborne, and Environmental Diseases.

“Using data to help prevent disease outbreaks and respond to public health emergencies are the kind of problems we built Palantir to help solve,” said Palantir USG President Akash Jain. “We’ve been proud to work with the public health experts at the CDC for over a decade and look forward to our continued partnership.”

Palantir Foundry enables data-driven decision-making by integrating data from siloed data sources and enabling granular access across various organizations. It is used by several federal health agencies, including the National Institutes of Health, the Department of Health and Human Services, and the Food and Drug Administration, and was also used by several military branches to mitigate the impact of the COVID-19 pandemic.

About Palantir

Palantir Technologies Inc. is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Media Contact

Lisa Gordon

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Infectious Diseases Health Data Management Technology Software

MEDIA:

Logo
Logo
Posted on

Accenture to Host Conference Call Thursday, June 24, to Discuss Third-Quarter Fiscal Year 2021 Results

Accenture to Host Conference Call Thursday, June 24, to Discuss Third-Quarter Fiscal Year 2021 Results

NEW YORK–(BUSINESS WIRE)–
Accenture (NYSE: ACN) will host a conference call at 8:00 a.m. EDT on Thursday, June 24, to discuss its third-quarter fiscal year 2021 financial results. A news release containing these results will be issued before the call.

To participate, please dial +1 (877) 692-8955 [+1 (234) 720-6979 outside the United States, Puerto Rico and Canada] and enter access code 4728020 approximately 15 minutes before the scheduled start of the call. The conference call will also be accessible live on the Investor Relations section of the Accenture Web site at www.accenture.com.

A replay of the conference call will be available online at www.accenture.com beginning at 11:00 a.m. EDT on Thursday, June 24, 2021. The replay will also be available via telephone by dialing +1 (866) 207-1041 [+1 (402) 970-0847 outside the United States, Puerto Rico and Canada] and entering access code 1334620 from 11:00 a.m. EDT Thursday, June 24 through Wednesday, Sept. 22, 2021.

About Accenture

Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 537,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com.

Stacey Jones

Accenture

+1 917 452 6561

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Professional Services Data Management Security Technology Software Networks Consulting

MEDIA:

Posted on

BD Hits 2 Billion Injection Device Milestone in Support of Global COVID-19 Vaccination Efforts

Company Now Supplying More Than 40 Countries for Pandemic Vaccination Campaigns

PR Newswire

FRANKLIN LAKES, N.J., June 8, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling 2 billion injection devices to support global COVID-19 vaccination efforts.

This new milestone reflects commitments to governments across the world, including the United States, Australia, Brazil, Canada, France, Germany, India, Philippines, Saudi Arabia, South Africa, Spain and the United Kingdom, among many others, as well as non-governmental organizations supporting vaccine deployment for developing countries. In total, BD is supporting pandemic orders for more than 40 countries, non-governmental organizations and other partners.  

“Expanding vaccination efforts are bringing restored hope and a long-awaited return to normalcy in multiple countries around the world,” said Rick Byrd, president of Medication Delivery Solutions for BD. “We are committed to continuing to support government partners and non-governmental organizations in these efforts to ensure health care providers on the front lines of this crisis have these much-needed injection devices to protect their patients from COVID-19.”

BD has delivered more than 900 million injection devices around the world to date, with the remaining orders to be delivered between now and the end of 2022 to support vaccine administration. These devices are being shipped to governments or appointed distribution partners where they will then be distributed to health care facilities based on each country’s individual distribution and allocation strategy. BD continues to be in discussions with government agencies and non-governmental organizations on the need to plan ahead to ensure supply availability and place orders for delivery in late 2022 and into the future.

As part of its efforts, BD continues to closely plan supply capabilities to help ensure maximum volumes can be dedicated to COVID-19 efforts, while minimizing disruption for routine health care, annual flu vaccinations and childhood immunization programs.

BD has also announced multiple capital investments to expand capacity for vaccination injection devices for COVID-19 and future pandemics. These include:

  • Adding new manufacturing lines for injection devices in the company’s Fraga, Spain manufacturing facility. When these lines ramp up now through 2022 it will increase output of these devices by nearly 500 million per year to support COVID-19 and other efforts, mainly for markets in Europe, Middle East and Africa, as well as for non-governmental organizations.

For this critical role and commitment to support vaccination efforts globally, BD was recently recognized at the 2021 World Vaccine Congress’ Vaccine Industry Excellence Awards as the “Best Production/Process Development.” The award recognized BD for its ability to extend its capacity to provide disposable syringes and pre-fillable syringes required for COVID-19 vaccinations, as well as its range of solutions covering the entire vaccine development.

BD is the largest manufacturer of injection devices in the world, producing multiple billions of syringes and needles annually through its global manufacturing network. To learn more about BD’s vaccination preparedness efforts, visit bd.com/vaccination.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at linkedin.com/company/bd1 and Twitter @BDandCo.


Forward-Looking Statements


This press release contains certain forward-looking statements regarding BD’s manufacturing operations and capacity. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, many of which are beyond the company’s control, as discussed in BD’s filings with the Securities and Exchange Commission. BD expressly disclaims any undertaking to update any such statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable laws or regulations.


Contacts:



Media:



Investors:

Troy Kirkpatrick

Kristen M. Stewart, CFA

VP, Public Relations

SVP, Strategy & Investor Relations

858.617.2361

201.847.5378


[email protected]


[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-hits-2-billion-injection-device-milestone-in-support-of-global-covid-19-vaccination-efforts-301307142.html

SOURCE BD (Becton, Dickinson and Company)

Posted on

City of Hope Honors Leonard Miller of The New Home Company with 2021 Spirit of Life® Award

City of Hope Honors Leonard Miller of The New Home Company with 2021 Spirit of Life® Award

Mr. Miller, NEW HOME’s President and Chief Executive Officer, is recognized for his commitment to support those in need.

IRVINE, Calif.–(BUSINESS WIRE)–
Last month during a special virtual gala attended by more than 500 guests, City of Hope honored Leonard Miller, President and Chief Executive Officer of The New Home Company (NEW HOME; NYSE: NWHM) with the 2021 Spirit of Life® Award. The fight against cancer is near and dear to Mr. Miller’s heart as the disease has touched close to home for him and his wife.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005301/en/

Leonard Miller, President and Chief Executive Officer of The New Home Company. (Photo: Business Wire)

Leonard Miller, President and Chief Executive Officer of The New Home Company. (Photo: Business Wire)

The Spirit of Life® Award is City of Hope’s most prestigious honor, presented to an esteemed community of industry leaders around the world who have made a significant commitment to support those in need. Honorees are selected for their notable contributions to the community in which they live and the profession in which they work. This year, City of Hope’s Construction Industries Alliance (CIA) recognized Mr. Miller for his contributions to the industry and boundless compassion for humanity.

“We’re honored to recognize Leonard for his outstanding contributions to our community, his industry and for his longstanding support of City of Hope,” said Annette Walker, President of City of Hope. “As a champion of City of Hope, Leonard understands the importance of our mission and knows that when we take a patient’s hand, we never let go. Thank you to Leonard, the team at The New Home Company and the leaders at Construction Industries Alliance for helping us speed our highly specialized care and groundbreaking research to more people and get closer to a world without cancer.”

As President and CEO of NEW HOME, Mr. Miller is responsible for leading all aspects of the publicly traded homebuilder’s operations. He has more than 30 years of experience in residential homebuilding and land development. He places a primary focus on people including the investment and development of team members, homeowners, trade partners and industry peers while giving back to the community.

“I’m truly honored to be recognized by the City of Hope and this award is really a reflection of those I have been surrounded by throughout the years,” said Mr. Miller. “I’m a true believer when it comes to the City of Hope. The love, care and support that it provides all of its patients is nothing less than exceptional. The work of its doctors, researchers and staff changes lives and I can’t think of a better cause to support.”

This year, the Spirit of Life® Gala raised more than $500,000 for City of Hope.

“Philanthropy has the power to change the world for the better and we are so grateful to this inspirational and dedicated group of homebuilders for their contributions,” said Sarah Sasman, Senior Executive Director of Philanthropy for City of Hope. “It is through their commitment and dedication that we will create a healthier tomorrow.”

About The New Home Company

NEW HOME is a publicly traded company listed on the New York Stock Exchange under the symbol “NWHM.” It is a new generation homebuilder focused on the design, construction and sale of innovative and consumer-driven homes in major metropolitan areas within select growth markets in California, Arizona and Colorado. NEW HOME was named 2019 Builder of the Year by Professional Builder and is a multi-year recipient of “The Eliant” for providing the Best Overall Customer Experience in North America in the Eliant Homebuyers’ Choice Awards. NEW HOME has won hundreds of awards in the homebuilding industry for its design and planning excellence, dozens of “Community of the Year” awards, and was recognized five straight years for creating the best community or master plan in all the United States. For more information, visit NWHM.com.

Mike Hoye

Paolucci Salling & Martin Communication Arts | Public Relations

(310) 346-0845 (mobile)

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Philanthropy Health Hospitals Residential Building & Real Estate Fund Raising Construction & Property

MEDIA:

Photo
Photo
Leonard Miller, President and Chief Executive Officer of The New Home Company. (Photo: Business Wire)
Posted on

Asensus Surgical to Join the Russell 2000® and Russell Microcap® Indexes

Asensus Surgical to Join the Russell 2000® and Russell Microcap® Indexes

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that the company will be added to the Russell 2000® and Russell Microcap® Indexes at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“We’re thrilled to be a part of the Russell 2000 Index and believe that our inclusion will increase our visibility and exposure to investors,” said Anthony Fernando, President and CEO of Asensus Surgical. “This milestone is a testament to our hard work to create value for our stockholders through our strategy and bring the Senhance System’s transformative technology to surgeons, hospitals, and patients globally.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 2000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com.

Forward-Looking Statements

This press release includes statements regarding our future plans and goals which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether our inclusion in the Russell 2000 Index will increase our visibility, value and exposure to investors. For a discussion of the risks and uncertainties associated with Asensus Surgical’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020, which we filed with the SEC on March 11, 2021. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:

Mark Klausner or Mike Vallie, 443-213-0499

[email protected]

or

MEDIA CONTACT:

Kristin Schaeffer

CG Life

[email protected]

KEYWORDS: United States North America North Carolina

INDUSTRY KEYWORDS: Biotechnology Health Surgery Medical Devices

MEDIA:

Logo
Logo
Posted on

Feed the Children, Tyson Foods and Americold Launch 10-City Tour to Help Feed Families in Rural Communities Across the U.S.

Initiative will provide essential supplies and almost 2 million meals to families during summer

SPRINGDALE, Ark., June 08, 2021 (GLOBE NEWSWIRE) — Feed the Children, Tyson Foods and Americold are partnering to launch an “Alliance to Defeat Hunger” with a 10-city tour across the United States to help feed families in rural communities. Throughout the tour the organizations will supplement nearly 2 million meals to families experiencing food insecurity.

Feed the Children and Tyson Foods have partnered for 19 years to provide protein to families across the country. Feed the Children and Americold also have a multi-year partnership to fight hunger that has included donations of critical funds, temperature-controlled transportation and warehouse space. The three organizations recently announced a partnership to expedite meal distribution via a unique supply chain model. With many families still reeling from the effects of COVID-19, the three organizations are now expanding their work together via the 10-city tour to ensure families have access to nutritious food this summer.  

In each city, Feed the Children, Tyson and Americold will hold distribution events with local community partners for over 1,200 people. At each event, families will receive a 25-pound box of non-perishable food; a 15-pound box of essentials such as shampoo, conditioner, lotion and personal-care items; Tyson products and additional items.

The companies will also partner with schools in each community to set up a pantry where children and families can access food, school supplies and personal hygiene products during or after school hours. The tour will kick-off in Springdale, Ark., on June 8 and end in Enid, Okla., Sept. 30.

“We’re proud to be a part of this tour that will help so many families in rural communities across the United States,” said Debra Vernon, senior director, corporate social responsibility, Tyson Foods. “We’re committed to supporting hunger relief efforts across the country, and this initiative will provide critical resources to those who need it most.”

“By partnering with Feed the Children and Tyson Foods in this alliance to defeat hunger, we’re able to expand our efforts to provide for families and children in need across the country. This tour is another way we’re demonstrating our commitment to give back and support the communities where our associates live and work,” said Fred Boehler, President and CEO of Americold.

“The Americold and Tyson Foods partnership means so much to Feed the Children, and more importantly, to the families we serve,” said Travis Arnold, president and CEO, Feed the Children. “Those living paycheck-to-paycheck do not have a safety net. Our partners are a critical part of providing compassionate support to those who are facing tough decisions about how to care for their families.”

The tour is focused on rural communities in America, where those in need have less access to nutritious food and limited support for feeding programs to help kids and families. The three companies also want to ensure that children have access to food and essentials during the summer months when school is not in session.

Tour dates and locations include:

  • June 8: Springdale, AR
  • June 23: Tolleson, AZ
  • July 13: New Holland, PA
  • July 20: Garden City, KS
  • July 28: Sanford, NC
  • August 5: Pasco, WA
  • August 11: Sioux City, IA
  • Sept 2: Amarillo, TX
  • Sept 9: Sebree, KY
  • Sept 30: Enid, OK

About Tyson Foods

Tyson Foods, Inc. is one of the world’s largest food companies and a recognized leader in protein. Founded in 1935 by John W. Tyson and grown under three generations of family leadership, the company has a broad portfolio of products and brands like Tyson®, Jimmy Dean®, Hillshire Farm®, Ball Park®, Wright®, Aidells®, ibp® and State Fair®. Tyson Foods innovates continually to make protein more sustainable, tailor food for everywhere it’s available and raise the world’s expectations for how much good food can do. Headquartered in Springdale, Arkansas, the company has 139,000 team members. Through its Core Values, Tyson Foods strives to operate with integrity, create value for its shareholders, customers, communities and team members and serve as a steward of the animals, land and environment entrusted to it. Visit www.tysonfoods.com.

About Americold

Americold is the world’s largest publicly-traded REIT focused on the ownership, operation, acquisitions and development of temperature-controlled warehouses. Based in Atlanta, Georgia, Americold owns and operates 238 temperature-controlled warehouses, with over 1.4 billion cubic feet of storage, in North America, Europe, Australia, New Zealand, and South America. Americold’s facilities are an integral component of the supply chain connecting food producers, processors, distributors and retailers to consumers. Visit www.americold.com for more information.

About Feed the Children

At Feed the Children, we feed hungry kids. We envision a world where no child goes to bed hungry. In the U.S. and internationally, we are dedicated to helping families and communities achieve stable lives and to reducing the need for help tomorrow, while providing food and resources to help them today. We distribute product donations from corporate donors to local community partners, we provide support for teachers and students, and we mobilize resources quickly to aid recovery efforts when natural disasters strike. Internationally, we manage child-focused community development programs in 10 countries. We welcome partnerships because we know our work would not be possible without collaborative relationships.

Visit feedthechildren.org for more information.

Media Contacts

Tyson Foods: Chattin Cato
Feed the Children: Carrie Snodgrass
Americold: Angie Hansen



Posted on

Visteon to present at Deutsche Bank Global Auto Industry Conference on June 16

VAN BUREN TOWNSHIP, Mich., June 08, 2021 (GLOBE NEWSWIRE) — Visteon Corporation (Nasdaq: VC), a global automotive electronics technology enterprise dedicated to creating more enjoyable, connected and safe driving experiences, will present at Deutsche Bank’s 2021 Global Auto Industry Conference on Wednesday, June 16. Sachin Lawande, president and CEO, and Jerome Rouquet, senior vice president and chief financial officer, will provide remarks starting at approximately 9:30 a.m. ET and participate in a question-and-answer session. The presentation and Q&A session are expected to last approximately 35 minutes.

A live audio webcast, along with the presentation material and other supplemental information, will be accessible through Visteon’s website at https://investors.visteon.com/events-presentations. A replay will be available following the event.

About Visteon

Visteon is a technology leader in automotive electronics dedicated to creating a more enjoyable, connected and safe driving experience. Our platforms leverage proven, scalable hardware and software solutions that enable the digital, electric and autonomous evolution of our global automotive customers. Visteon products align with key industry trends and include digital instrument clusters, displays, Android-based infotainment systems, domain controllers, advanced driver assistance systems (ADAS) and battery management systems. The company is headquartered in Van Buren Township, Michigan, and has approximately 10,000 employees at more than 40 facilities in 18 countries. Visteon reported sales of approximately $2.5 billion and booked $4.6 billion of new business in 2020. Learn more at https://investors.visteon.com/.

Follow Visteon:

https://www.linkedin.com/company/visteon 
https://twitter.com/visteon
https://www.facebook.com/VisteonCorporation
https://www.youtube.com/user/Visteon
http://www.slideshare.net/VisteonCorporation
https://www.instagram.com/visteon/
https://mp.weixin.qq.com/?lang=en_US
https://m.weibo.cn/u/6605315328
http://i.youku.com/u/UNDgyMjA1NjUxNg==?spm=a2h0k.8191407.0.0

Media:

Dave Barthmuss
[email protected]
805-660-1914

Investor Relations:

Kris Doyle
201-247-3050
[email protected]